Weller, Jonathan
Katzendobler, Sophie
Blobner, Jens
Thiele, Frederic
Becker, Hannes
Quach, Stefanie
Egensperger, Rupert
Niyazi, Maximilian
Suchorska, Bogdana
Thon, Niklas
Weller, Michael
Tonn, Joerg-Christian
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 1 August 2022
Accepted: 30 August 2022
First Online: 16 September 2022
Declarations
:
: Maximilian Niyazi—MN has received honoraria for lectures or advisory board participation or consulting from Brainlab and Novocure. Michael Weller—MW has received research grants from Abbvie, Adastra, Apogenix, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure and Quercis, and honoraria for lectures or advisory board participation or consulting from Abbvie, Adastra, Basilea, Bristol Meyer Squibb (BMS), Celgene, Medac, Merck, Sharp & Dohme (MSD), Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen, Roche, Tocagen and yMabs. Joerg-Christian Tonn—Consultant/speaker honoraria from BrainLab and Carthera, and royalties from Springer Publisher Intl. Jonathan Weller, Sophie Katzendobler, Jens Blobner, Frederic Thiele, Hannes Becker, Stefanie Quach, Rubert Egensperger, Bogdana Suchorska, Niklas Thon—No disclosures.
: Ethics approval was obtained by the ethics committee of the Ludwig Maximilian University of Munich (Project Number 21-0612).
: Consent to participate in retrospective studies is given prospectively by all patients treated at the Department of Neurosurgery of the Ludwig Maximilian University of Munich through a local prospective tumor registry.
: All authors have consented in submitting this manuscript for publication in the Journal of Neuro-Oncology.
: The present study was conducted retrospectively.